Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
New York is making major strides in opioid use disorder (OUD) treatment — expanding methadone access, bringing medications into prisons and jails, and now piloting a cash-incentive program for stimulant use disorder. State officials also outlined plans to protect Medicaid coverage for up to a million residents facing new federal work requirements starting in 2027.
New York is doubling down on addiction treatment. At the annual COMPA Symposium, state officials celebrated significant gains in opioid use disorder (OUD) care — including 140 outpatient methadone programs and MOUD access in all 41 state prisons and 58 jails. From 2022 to 2025, the number of incarcerated people receiving MOUD jumped 7x, driven largely by expanded buprenorphine access. Officials credited flexible take-home dosing rules — first introduced during COVID-19 and made permanent by SAMHSA in 2024 — as a key driver of progress, particularly in reducing overdose deaths among Black New Yorkers.
Next up: tackling stimulant use disorder, which affects slightly more Americans than OUD but has zero FDA-approved medications. New York is launching an 18-month contingency management pilot across eight outpatient clinics, where patients earn gift cards (up to $750 total) for stimulant-negative urine tests — a model backed by decades of research.
By the Numbers:
Why it matters: These initiatives reflect a shift toward evidence-based, flexible addiction care — but their long-term success hinges on Medicaid funding stability, with New York's 1115 waiver (enabling contingency management reimbursement) set to expire in March 2027.
